RXULTI

Welcome to the Brand page for “RXULTI”, which is offered here for Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, lennox-gastaut syndrome (lgs), sclerosis, porphyria, huntington's disease and disorder, insomnia, parkinson's disease and disorder, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, adhd, ptsd, agitation, cancer, migraine, pain, alcoholism and dependency; diagnostic agents, reagents, preparations and substances for medical purposes;.

Its status is currently believed to be active. Its class is unavailable. “RXULTI” is believed to be currently owned by “Otsuka Pharmaceutical Co., Ltd.”